Medrad, IBA to supply PET infusion system for UPMC
The University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center has installed Intego PET infusion system from Medrad, which has partnered with IBA Molecular to provide the radiopharmaceutical supply.
The Louvain-la-Neuve, Belgium-based IBA will supply UPMC with fluorodeoxyglucose (FDG) in a multi-dose vial in a Tungsten vial shield.
Use of the system minimizes the need to manually prepare and handle individual FDG doses, reducing potential radiation exposure to hospital personnel, according to the Warrendale, Pa.-based Medrad.
The Intego system automates the administration of FDG for PET/CT imaging procedures. By automating and controlling FDG dosing and infusion, Medrad said its Intego system administers IBA’s FDG to patients throughout the day.
Medrad said its Intego system extracts a patient dose from a multi-dose vial and administers the dose, via infusion, directly to the patient; minimizing the need for manual dose preparation and associated handling, as well as protecting the technologist from the corresponding radiation exposure.
The Louvain-la-Neuve, Belgium-based IBA will supply UPMC with fluorodeoxyglucose (FDG) in a multi-dose vial in a Tungsten vial shield.
Use of the system minimizes the need to manually prepare and handle individual FDG doses, reducing potential radiation exposure to hospital personnel, according to the Warrendale, Pa.-based Medrad.
The Intego system automates the administration of FDG for PET/CT imaging procedures. By automating and controlling FDG dosing and infusion, Medrad said its Intego system administers IBA’s FDG to patients throughout the day.
Medrad said its Intego system extracts a patient dose from a multi-dose vial and administers the dose, via infusion, directly to the patient; minimizing the need for manual dose preparation and associated handling, as well as protecting the technologist from the corresponding radiation exposure.